Replies to post #211281 on Amarin Corp Plc (AMRN)

[moonotaur]

Do you think someone knows something that you or this board doesn’t?

Or are you getting caught up in the FDA/AMRN drama?

Why do you think differently about the drug potential?

This is what owning a 60% retail ownership stock feels like. Amrn is small peanuts. $45m in trade flows lost mkt cap of $265M today...this reeks of panic.

[NickHous]

Hindsight over a month ago in 23s!!!!

[mrmainstreet]

When it crosses my mind I remember the REDUCE-IT results and the p-rating of those results, the script growth, the acceptance the ADA/AHA, and the chances of a buyout down the road.

But I stay off options and margin, so just hold shares. It allows me to be patient.

But I don't blame anyone for cashing in and taking their profits from 9/24 when we spiked up.

[KCSVEN]

And capitulation signs almost there.....

It's rough having stock drop from 23 to 14 in such a short time, anyone who had an account that has seen the money balance drop and drop is going to hesitate and think I'm done, just natural. Short interest is useful but when shorts are wrong they are every wrong. You think Amarin said we are selling no matter what tomorrow or 6 months from now, they would get less than 10 billion? In worst case scenario Amarin becomes a cash cow OTC EPA company generating up to a .5 to 1 billion a year forever.

ADCOM is going to be very positive and expect unanimous vote for an expended label, followed by FDA approval, odds almost 100% in my mind so let the algorithms short, let the street that says "Dilution followed by surprise Adcom, oh they are screwed" pile in. They have not done the due diligence to the level many here have.
If I'm right the short squeeze will be awesome AND the new shorts at that point will be minimal as growth rates will become staggering.

[Whalatane]

Montana ...if you liked AMRN at $23 ...you have to love it as a bargain down here around $12.50-$14.

Tell me ...what has changed ?...besides what we already know ...capital raise and Adcom required.

Reduce it results are still the same and Dr Bhatt stands by them
ICER report is very positive ...Vascepa is a very cost effective drug
Company now has over $600 m. COH ...so no need to raise funds .

The unknowns .........the actual date of the Adcom being confirmed and the risk that it may be delayed .
The unknowns re patent challenges and possible settlement .

A delay in Adcom is not enough for me to sell the stock .
Patent issues ....don't know ...Defending against composition of matter might be hard ( see Will-Lar posts ) but defending method of action patents should be easy IMHO .

So bottom line ...if you decide to sell ...please post when you do ..
thx
Kiwi

[Biobillionair]

Everyday...but I am holding...too much foul play for Amarin not to get the ultimate victory.--BB